Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Huai-Che Shih, PhD
Advertisement
Articles by Huai-Che Shih, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Special Report: The Oncology Care Model, 10 Years Later
2
Long-Term Extension Data Support Durable Benefit of Rilzabrutinib in Persistent, Chronic ITP: David Kuter, MD, DPhil
3
Patients on GLP-1s Increasingly Carry Diagnoses for New Indications
4
Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD
5